Open AccessP1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
Author(s) -
Opat S.,
Hu B.,
Tedeschi A.,
Linton K. M.,
McKay P.,
Chan H.,
Jin J.,
Sun M.,
SobierajTeague M.,
Zinzani P. L.,
Coleman M.,
Browett P.,
Ke X.,
Portell C. A.,
Thieblemont C.,
Ardeshna K.,
Bijou F.,
Walker P.,
Hawkes E. A.,
Ho S.J.,
Zhou K.S.,
Co M.,
Xu J.,
Liang Z.,
Anderson J.,
Tankersley C.,
Huang J.,
Trotman J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847516.77095.99
Subject(s) - medicine , clinical endpoint , ibrutinib , progression free survival , regimen , oncology , phases of clinical research , salvage therapy , clinical trial , overall survival , chemotherapy , leukemia , chronic lymphocytic leukemia